1. Home
  2. MDWD vs TRVG Comparison

MDWD vs TRVG Comparison

Compare MDWD & TRVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • TRVG
  • Stock Information
  • Founded
  • MDWD 2000
  • TRVG 2005
  • Country
  • MDWD Israel
  • TRVG Germany
  • Employees
  • MDWD N/A
  • TRVG N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • TRVG EDP Services
  • Sector
  • MDWD Health Care
  • TRVG Technology
  • Exchange
  • MDWD Nasdaq
  • TRVG Nasdaq
  • Market Cap
  • MDWD 179.1M
  • TRVG 159.2M
  • IPO Year
  • MDWD 2014
  • TRVG N/A
  • Fundamental
  • Price
  • MDWD $17.80
  • TRVG $1.76
  • Analyst Decision
  • MDWD Strong Buy
  • TRVG Buy
  • Analyst Count
  • MDWD 1
  • TRVG 4
  • Target Price
  • MDWD $28.00
  • TRVG $2.75
  • AVG Volume (30 Days)
  • MDWD 60.7K
  • TRVG 41.2K
  • Earning Date
  • MDWD 08-14-2024
  • TRVG 10-30-2024
  • Dividend Yield
  • MDWD N/A
  • TRVG N/A
  • EPS Growth
  • MDWD N/A
  • TRVG N/A
  • EPS
  • MDWD N/A
  • TRVG N/A
  • Revenue
  • MDWD $20,141,000.00
  • TRVG $503,102,968.00
  • Revenue This Year
  • MDWD $30.16
  • TRVG N/A
  • Revenue Next Year
  • MDWD $18.44
  • TRVG $6.99
  • P/E Ratio
  • MDWD N/A
  • TRVG N/A
  • Revenue Growth
  • MDWD N/A
  • TRVG N/A
  • 52 Week Low
  • MDWD $7.45
  • TRVG $1.79
  • 52 Week High
  • MDWD $24.00
  • TRVG $5.90
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 50.02
  • TRVG 23.07
  • Support Level
  • MDWD $16.25
  • TRVG $1.94
  • Resistance Level
  • MDWD $17.90
  • TRVG $1.98
  • Average True Range (ATR)
  • MDWD 0.97
  • TRVG 0.05
  • MACD
  • MDWD -0.05
  • TRVG -0.02
  • Stochastic Oscillator
  • MDWD 36.98
  • TRVG 0.00

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About TRVG trivago N.V.

trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments namely the Americas, Developed Europe, and the Rest of the World. It derives a majority of revenue from the Developed Europe segment. The Developed Europe segment is comprised of Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, Malta, the Netherlands, Norway, Portugal, Spain, Sweden, and others.

Share on Social Networks: